CZ297382B6 - Rychle se dispergující orální pevná dávková formafarmaceutického prostredku pro lécení Parkinsonovy nemoci - Google Patents

Rychle se dispergující orální pevná dávková formafarmaceutického prostredku pro lécení Parkinsonovy nemoci Download PDF

Info

Publication number
CZ297382B6
CZ297382B6 CZ0270597A CZ270597A CZ297382B6 CZ 297382 B6 CZ297382 B6 CZ 297382B6 CZ 0270597 A CZ0270597 A CZ 0270597A CZ 270597 A CZ270597 A CZ 270597A CZ 297382 B6 CZ297382 B6 CZ 297382B6
Authority
CZ
Czechia
Prior art keywords
selegiline
dosage form
parkinson
usp
disease
Prior art date
Application number
CZ0270597A
Other languages
Czech (cs)
English (en)
Other versions
CZ270597A3 (cs
Inventor
Mary Brewer@Francesca
Stewart Johnson@Edward
Clarke@Anthony
Original Assignee
R.P. Scherer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ297382(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9504235.4A external-priority patent/GB9504235D0/en
Application filed by R.P. Scherer Limited filed Critical R.P. Scherer Limited
Publication of CZ270597A3 publication Critical patent/CZ270597A3/cs
Publication of CZ297382B6 publication Critical patent/CZ297382B6/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CZ0270597A 1995-03-02 1996-03-01 Rychle se dispergující orální pevná dávková formafarmaceutického prostredku pro lécení Parkinsonovy nemoci CZ297382B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9504235.4A GB9504235D0 (en) 1995-03-02 1995-03-02 Pharmaceutical compositon
GBGB9517063.5A GB9517063D0 (en) 1995-03-02 1995-08-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
CZ270597A3 CZ270597A3 (cs) 1998-01-14
CZ297382B6 true CZ297382B6 (cs) 2006-11-15

Family

ID=26306612

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0270597A CZ297382B6 (cs) 1995-03-02 1996-03-01 Rychle se dispergující orální pevná dávková formafarmaceutického prostredku pro lécení Parkinsonovy nemoci

Country Status (26)

Country Link
US (3) US20010021722A1 (fr)
EP (1) EP0814789B2 (fr)
JP (1) JP3273141B2 (fr)
CN (1) CN1171586C (fr)
AT (1) ATE241346T1 (fr)
AU (1) AU702161B2 (fr)
BG (1) BG63862B1 (fr)
BR (1) BR9607057A (fr)
CA (1) CA2214026C (fr)
CZ (1) CZ297382B6 (fr)
DE (1) DE69628415T3 (fr)
DK (1) DK0814789T4 (fr)
EE (1) EE04039B1 (fr)
ES (1) ES2199283T5 (fr)
GE (1) GEP20012374B (fr)
HU (1) HU228852B1 (fr)
IS (1) IS2789B (fr)
MX (1) MX9706647A (fr)
NO (1) NO316804B1 (fr)
NZ (2) NZ302723A (fr)
PL (1) PL183266B1 (fr)
PT (1) PT814789E (fr)
SI (1) SI0814789T2 (fr)
SK (1) SK284383B6 (fr)
TR (1) TR199700878T1 (fr)
WO (1) WO1996026720A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
AU723047B2 (en) 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
WO1997017067A1 (fr) * 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Administration sublinguale et buccale de selegiline
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
GB9717770D0 (en) * 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
GB9802088D0 (en) * 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
CN1251695C (zh) * 1999-04-21 2006-04-19 株式会社柳柳 用于治疗痴呆的含有司来吉兰和银杏提取物的药物组合物
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
AU2005309817B2 (en) * 2004-11-24 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
CA2616918A1 (fr) 2005-07-01 2007-01-11 Jenrin Discovery Inhibiteurs mao-b utiles dans le traitement de l'obesite
CN1911211B (zh) * 2006-08-25 2010-04-14 重庆医药工业研究院有限责任公司 雷沙吉兰口服固体制剂
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
US20070190187A1 (en) * 2006-09-07 2007-08-16 Kneller Bruce W Formulation for enhanced delivery of phenethylamine
EP2053033A1 (fr) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Composants à utiliser dans l'imagerie, le diagnostic et/ou le traitement des maladies du système nerveux central ou des tumeurs
CA2761538A1 (fr) * 2009-05-20 2010-12-23 Lingual Consegna Pty Ltd Formulations therapeutiques ameliorees
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2450332A1 (fr) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Composants à utiliser dans l'imagerie, le diagnostic et/ou le traitement des maladies du système nerveux central (F-D2-déprényle)
WO2013175493A1 (fr) 2012-04-09 2013-11-28 Cadila Healthcare Limited Compositions pharmaceutiques orales stables
EP3432931A1 (fr) 2016-03-26 2019-01-30 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques pour un dérivé de n-propargylamine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153578A (en) * 1962-03-30 1969-05-29 Chinoin Gyogyszer Es Vegyeszet Phenyl-Isopropylamine Derivatives
EP0067105A2 (fr) * 1981-06-01 1982-12-15 Merrell Dow France Et Cie Inhibiteurs de MAO du type allylamine
EP0252290A2 (fr) * 1986-06-10 1988-01-13 CHIESI FARMACEUTICI S.p.A. Compositions pharmaceutiques contenant le lévodopa méthyl ester, leur préparation et leurs applications thérapeutiques
WO1988004552A1 (fr) * 1986-12-19 1988-06-30 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Composition servant a traiter le mal de mer
WO1990001928A1 (fr) * 1988-08-17 1990-03-08 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Composition servant a traiter la schizophrenie
EP0436492A2 (fr) * 1990-01-03 1991-07-10 Teva Pharmaceutical Industries Limited R-Enantiomère de N-propargyl-1-aminoindane, son préparation et composition pharmaceutique le contenant
WO1992002224A1 (fr) * 1990-08-10 1992-02-20 Farmitalia Carlo Erba S.R.L. Inhibiteur reversible antiparkinsonien a monoamine-oxydase
WO1995011016A1 (fr) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomere de n-propargyl-1-amino-indane, sels, compositions et utilisation de ce compose

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (fr) * 1977-07-20 1981-03-10 George K. E. Gregory Emballages
IE53696B1 (en) * 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
JP2660419B2 (ja) * 1988-04-02 1997-10-08 旭電化工業株式会社 安定化された合成樹脂組成物
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5192550A (en) 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
AU666509B2 (en) 1991-12-24 1996-02-15 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1997017067A1 (fr) * 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Administration sublinguale et buccale de selegiline

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153578A (en) * 1962-03-30 1969-05-29 Chinoin Gyogyszer Es Vegyeszet Phenyl-Isopropylamine Derivatives
EP0067105A2 (fr) * 1981-06-01 1982-12-15 Merrell Dow France Et Cie Inhibiteurs de MAO du type allylamine
EP0252290A2 (fr) * 1986-06-10 1988-01-13 CHIESI FARMACEUTICI S.p.A. Compositions pharmaceutiques contenant le lévodopa méthyl ester, leur préparation et leurs applications thérapeutiques
WO1988004552A1 (fr) * 1986-12-19 1988-06-30 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Composition servant a traiter le mal de mer
WO1990001928A1 (fr) * 1988-08-17 1990-03-08 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Composition servant a traiter la schizophrenie
EP0436492A2 (fr) * 1990-01-03 1991-07-10 Teva Pharmaceutical Industries Limited R-Enantiomère de N-propargyl-1-aminoindane, son préparation et composition pharmaceutique le contenant
WO1992002224A1 (fr) * 1990-08-10 1992-02-20 Farmitalia Carlo Erba S.R.L. Inhibiteur reversible antiparkinsonien a monoamine-oxydase
WO1995011016A1 (fr) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomere de n-propargyl-1-amino-indane, sels, compositions et utilisation de ce compose

Also Published As

Publication number Publication date
BR9607057A (pt) 1998-06-09
CA2214026A1 (fr) 1996-09-06
IS4553A (is) 1997-08-27
HU228852B1 (en) 2013-06-28
HUP9801227A3 (en) 2000-02-28
SK115897A3 (en) 1998-03-04
CN1171586C (zh) 2004-10-20
DE69628415D1 (de) 2003-07-03
US20040091525A1 (en) 2004-05-13
PT814789E (pt) 2003-09-30
NO974010D0 (no) 1997-09-01
NZ329471A (en) 1999-10-28
CN1178461A (zh) 1998-04-08
GEP20012374B (en) 2001-03-25
AU4884696A (en) 1996-09-18
EE04039B1 (et) 2003-06-16
EP0814789B2 (fr) 2008-01-09
DK0814789T3 (da) 2003-09-01
SI0814789T1 (en) 2003-12-31
BG101937A (en) 1998-07-31
PL322046A1 (en) 1998-01-05
NO316804B1 (no) 2004-05-18
CA2214026C (fr) 2007-10-16
AU702161B2 (en) 1999-02-18
TR199700878T1 (xx) 1998-01-21
SI0814789T2 (sl) 2008-04-30
DE69628415T3 (de) 2008-06-26
JPH10506409A (ja) 1998-06-23
WO1996026720A1 (fr) 1996-09-06
US20010021722A1 (en) 2001-09-13
ES2199283T3 (es) 2004-02-16
MX9706647A (es) 1998-06-30
DK0814789T4 (da) 2008-05-19
HUP9801227A2 (hu) 1999-06-28
EP0814789A1 (fr) 1998-01-07
ES2199283T5 (es) 2008-05-16
IS2789B (is) 2012-06-15
EP0814789B1 (fr) 2003-05-28
US20080187573A1 (en) 2008-08-07
EE9700187A (et) 1998-02-16
CZ270597A3 (cs) 1998-01-14
ATE241346T1 (de) 2003-06-15
PL183266B1 (pl) 2002-06-28
BG63862B1 (bg) 2003-04-30
NZ302723A (en) 1998-04-27
DE69628415T2 (de) 2004-03-11
JP3273141B2 (ja) 2002-04-08
SK284383B6 (sk) 2005-02-04
NO974010L (no) 1997-10-30

Similar Documents

Publication Publication Date Title
US20080187573A1 (en) Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitor component
US6316027B1 (en) Fast-dissolving dosage forms for dopamine agonists
BG103570A (bg) Галенични форми и метод за подобряване на нарушената ерекция при мъже
JP5474033B2 (ja) 置換イミダゾール誘導体を含む改良された製剤
US9480661B2 (en) Solid dosage formulations containing weight-loss drugs
US9820937B2 (en) Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
CN100548281C (zh) 用于递送催眠药穿过口腔粘膜的组合物及其用法
AU2012241189A1 (en) Fast Dissolving Solid Dosage Form
KR100418210B1 (ko) 모노아민산화물b억제제로구성된제약학적조성물
EP1028719A1 (fr) Traitement de l'hyperactivite induite par les troubles d'attention et de la narcolepsie
CZ247299A3 (cs) Použití farmaceutické směsi pro ústní podání

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20160301